Teleflex Incorporated (TFX)
| Market Cap | 5.28B -5.0% |
| Revenue (ttm) | 2.25B +110.9% |
| Net Income | -1.03B |
| EPS | -23.41 |
| Shares Out | 42.37M |
| PE Ratio | n/a |
| Forward PE | 13.56 |
| Dividend | $1.36 (1.09%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 1,800,974 |
| Open | 125.03 |
| Previous Close | 125.59 |
| Day's Range | 124.01 - 125.83 |
| 52-Week Range | 100.18 - 145.00 |
| Beta | 0.81 |
| Analysts | Hold |
| Price Target | 153.55 (+23.31%) |
| Earnings Date | Nov 5, 2026 |
About TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and col... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TFX stock is "Hold." The 12-month stock price target is $153.55, which is an increase of 23.31% from the latest price.
News
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective...
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen,...
Teleflex Earnings Call Transcript: Q2 2026
Q2 saw strong Vascular and Surgical growth, offset by Interventional integration delays, leading to lowered revenue guidance but higher EPS outlook. Strategic divestitures and capital returns are progressing, with innovation milestones achieved. 2026 is a transition year, with significant improvement expected in 2027.
Teleflex Earnings release: Q2 2026
Teleflex released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Teleflex Slides: Q2 2026
Teleflex has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Teleflex Quarterly report: Q2 2026
Teleflex has published its Q2 2026 quarterly earnings report on August 6, 2026.
Teleflex Announces Quarterly Dividend
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. Th...
Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations f...
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow's MedTech Innovators
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks...
Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM busin...
Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has received Biologics License Application (BLA) approval for EZPL...
Teleflex Announces Second Quarter 2026 Earnings Conference Call Information
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on...
Teleflex Awarded National Central Venous Access Agreement with Premier, Inc.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc. Effective July 1, 2026, the ...
Teleflex Publishes 2025 Global Impact Report
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines r...
Teleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (NCT07258290), a...
Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the First-in-Human BIOMAG™-I Clinic...
Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due ...
Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032...
Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical da...
Teleflex Earnings Call Transcript: Q1 2026
Q1 2026 saw 32.3% revenue growth (GAAP) and 5.1% pro forma adjusted growth, with adjusted EPS down 3.5% year-over-year. Strategic divestitures and restructuring are on track, with significant margin and EPS improvements expected in 2027.
Teleflex Earnings release: Q1 2026
Teleflex released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Teleflex Slides: Q1 2026
Teleflex has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Teleflex Quarterly report: Q1 2026
Teleflex has published its Q1 2026 quarterly earnings report on May 7, 2026.
Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations fi...
Teleflex Appoints Jason Weidman as President and CEO
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) today announced that Jason Weidman has been appointed President and Chief Executive Officer, effective June 8, 2026. He will succeed Stua...